Inflammation and immunology (I&I) biologics development
Strategic Profile
The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. The dual-business-unit model leverages a mature CDMO operation to fund immunology research focused on NanoAbs (VHH antibody fragments). Scinai Immunotherapeutics announced a new peer-reviewed publication validating PC111, their first-in-class human anti-Fas Ligand monoclonal antibody, as a potential disease-modifying therapy for pemphigus and SJS/TEN.
Cyborg Score Rationale
In March 2026, Scinai received a Nasdaq notification indicating the Company is not in compliance with the Nasdaq Capital Market's minimum bid price requirement because the closing bid price of the American Depositary Shares was below $1.00 per share for 30 consecutive business days. In April 2026, Scinai entered into a private placement and warrant inducement financing expected to close on or about April 27, 2026, raising approximately $2.61 million in aggregate gross proceeds. The company faces delisting risk but continues advancement of CDMO operations and early-stage immunotherapy pipeline.
Top Insights
Scinai has been provided an initial compliance period of 180 calendar days, or until September 8, 2026, to regain compliance with the minimum bid price requirement.
Scinai reports advances in its NanoAb-based I&I pipeline, including anti‑IL‑17 programs for psoriasis and additional NanoAbs arising from collaborations with the Max Planck Society and University Medical Center Göttingen.
Revenues for the nine months ended September 30, 2025 were $1,049 thousand, compared to $452 thousand for the nine months ended September 30, 2024, reflecting continued expansion of Scinai Bioservices.
In 2025, Scinai received a non-dilutive Israel Innovation Authority grant of approximately $246,000, with installation and qualification of an advanced small-batch sterile fill-and-finish system expected in Q1 2026 and commercial operation planned in Q2 2026.
Named Competitors
Enbrel/Remicade — TNF-inhibitor biologics for rheumatoid arthritis and inflammation
Dupixent — IL-4 receptor antagonist for allergic and inflammatory diseases
Opzelura — JAK inhibitor for inflammatory skin conditions
Lonza CDMO Services — Large-scale contract development and manufacturing organization
Recent Developments
(February 2026) Scinai Bioservices expansion with fillable-finish capacity upgrades
(March 2026) Received Nasdaq minimum bid price non-compliance notification with 180-day cure period through September 8, 2026
(April 2026) Closed $2.61 million private placement financing for CDMO platform expansion and immunotherapy advancement
Open the full interactive Scinai Immunotherapeutics Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.